Comparison Between ROLL Versus Magnetic Seed for Preoperative Localization of Non-palpable Breast Lesion by Randomized Clinical Study.
SEED02
A Monocentric, Prospective, Randomized Clinical Study Comparing ROLL (Radioguided Occult Lesion Localization) With Magnetic Markers for Preoperative Localization of Non-palpable Breast Lesions in Patients Undergoing Breast Conservative Surgery.
1 other identifier
observational
262
1 country
1
Brief Summary
Several localization techniques are now in use for localization of non-palpable breast lesions. Several studies have compared wire guided localization (WGL), which has been for years the gold standard for non-palpable breast lesions' localization, with more modern techniques. Scientific evidence supports the efficacy of the new "wire-free" techniques, which appear to be comparable to the WGL in terms of safe surgical resection, while overcoming limitations associated with logistic difficulties and patient discomfort. There is still limited data in literature on the comparative effectiveness of these modern techniques, and there is no strong evidence that one is superior to the others. In particular, no randomized trials of comparison between ROLL and magnetic seed localization are currently available. The aim of this randomized study is to compare ROLL with magnetic seed to assess their efficacy for non-palpable breast lesions' localization.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2023
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 31, 2023
CompletedFirst Submitted
Initial submission to the registry
June 23, 2023
CompletedFirst Posted
Study publicly available on registry
July 12, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2028
ExpectedJune 23, 2026
May 1, 2026
3 years
June 23, 2023
June 19, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Free-surgical margins
Number of surgical procedures in which surgical margins are disease-free ("no ink on tumor" for invasive cancer and margin of 2 mm for in situ-carcinoma).
3 years
Secondary Outcomes (7)
Excess breast resection
3 years
Surgery Time
3 years
Hospitalization days
3 years
Complications
3 years
Reintervention
3 years
- +2 more secondary outcomes
Study Arms (2)
ROLL
Prior to surgery, an ultrasound-guided localization will be performed and albumin marked with Technetium 99m will be injected close to the tumor and in the subareolar area. During surgery, a specific probe will be used to locate the lesion and sentinel lymph node.
SEED
During diagnostic biopsy or prior to surgery, a magnetic clip will be placed in the breast lesion; during surgery, localization will be performed using a specific probe, while sentinel lymph node localisation, when needed, will be performed even with indocyanine green dye (ICG) or methylene blue dye
Interventions
Every patients with non-palpable breast lesion will undergo to conservative breast surgery after lesion's localization
Eligibility Criteria
Breast cancer patients with non-palpable lesions candidated for surgery
You may qualify if:
- Female;
- Non-palpable breast lesions;
- Indication to lesion's surgical excision (lumpectomy, quadrantectomy)
- Preoperative diagnosis on histology or cytology of borderline lesion (B3 or C3) or malignant lesion (B4-B5 or C4-C5);
- Written informed consent.
You may not qualify if:
- Benign lesion at diagnosis on preoperative core biopsy (B2) or fine needle aspiration (C2);
- Clinically palpable breast lesion;
- Breast lesion localization for planned neoadjuvant chemotherapy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Istituti Clinici Scientifici Maugeri SpA
Pavia, Lombardy, 27100, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
June 23, 2023
First Posted
July 12, 2023
Study Start
May 31, 2023
Primary Completion
May 31, 2026
Study Completion (Estimated)
May 31, 2028
Last Updated
June 23, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will not share